Showing 1721-1730 of 2105 results for "".
- Last Patient Fully Assessed in Trial of Accordion Formulation of Levodopa/Carbidopa for Parkinson's Diseasehttps://practicalneurology.com/news/last-patient-fully-assessed-in-trial-of-accordion-formulation-of-levodopacarbidopa-for-parkinsons-disease/2468878/The final patient completed their last physician visit in a pivotal phase 3 clinical trial for the accordion pill formulation of carbidopa/levodopa (AP-CD/LD) (Intec Pharma, Jerusalem, Israel) for treating advanced Parkinson’s disease (PD). A gastric-retentive drug delivery sy
- FDA Expands Selumetinib Approval to Younger Pediatric Patients with NF1https://practicalneurology.com/news/fda-expands-selumetinib-approval-to-younger-pediatric-patients-with-nf1/2483375/The Food and Drug Administration (FDA) announced the expanded approval of Koselugo (selumetinib; AstraZeneca, Wilmington, DE) to include pediatric patients aged 1 year and older with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The ther
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Cell Therapy for ALS Associated with Increased Survival at 5 Yearshttps://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from
- 6-Year Data Reported for Kesimpta Treatment of Individuals with Early, Non-Highly Active MShttps://practicalneurology.com/news/6-year-data-reported-for-kesimpta-treatment-of-individuals-with-early-non-highly-active-ms/2474006/Six-year open-label extension (OLE) results from the ALITHIOS clinical trial (NCT03650114) demonstrated that treatment with Kesimpta (ofatumumab; Novartis, East Hanover, NJ) was safe and effective for individuals with early multiple sclerosis (MS) and non-highly active disease taking continuous t
- 2-Year Data Demonstrated Achievement of Key Motor Milestones in Children with SMA Treated with Evrysdihttps://practicalneurology.com/news/2-year-findings-show-evrysdi-treatment-linked-to-achievement-of-key-motor-milestones-in-children-with-sma/2470611/Two-year data from the ongoing phase 2 RAINBOWFISH clinical trial (NCT03779334) showed that the majority of children with spinal muscular atrophy (SMA) treated with Evrysdi (risdiplam; Genentech, South San Francisco, CA) presymptomatically as infants achieved key motor milestones. According to th
- 5 Year Data Show Zeposia Treatment Was Associated with Reduced Brain Volume Loss In Patients with RMShttps://practicalneurology.com/news/5-year-data-reveal-zeposia-treatment-was-associated-with-reduced-brain-volume-loss-in-patients-with-rms/2470586/Results from the phase 3 DAYBREAK open-label extension trial for Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) showed sustained reductions in brain volume loss and consistent safety profiles for up to 5 years of continuous treatment in individuals with relapsing forms of multiple scleros
- Leqembi Treatment Associated with Sustained Reduction in Cognitive Decline According to 3-Year OLE Resultshttps://practicalneurology.com/news/leqembi-treatment-associated-with-sustained-reduction-in-cognitive-decline-according-to-3-year-ole-results/2470545/New 3-year open-label extension (OLE) results from the Clarity AD clinical trial (NCT03887455) presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) showed sustained reductions in cognitive decline in participants with early Alzheimer disease (AD) trea
- Evrysdi Therapy for Type 1 Spinal Muscular Atrophy Associated with Favorable 5-Year S&E Datahttps://practicalneurology.com/news/evrysdi-therapy-for-type-1-spinal-muscular-atrophy-associated-with-favorable-5-year-se-data/2470501/Five-year data from the open-label extension of the phase 2 FIREFISH (NCT02913482) clinical trial confirms the sustained efficacy and safety profile of Evrysdi (ridisplam; Genentech, South San Francisco, CA), a treatment for children with Type 1 spinal muscular atrophy (SMA). The results demonstr
- Ten-Year Data Demonstrate Ocrevus Treatment Reduced Disability in Individuals with Multiple Sclerosishttps://practicalneurology.com/news/ten-year-data-demonstrate-ocrevus-treatment-reduced-disability-in-individuals-with-multiple-sclerosis/2470444/According to long-term study results, earlier treatment with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in greater reductions in disability progression over 10 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) compa